All In Biotech

Drug Trial Radar · NCT06791291

Efficacy and Safety of Teplizumab in Japanese Participants With Stage 2 Type 1 Diabetes

Efficacy and Safety of Teplizumab in the Treatment of Japanese Pediatric and Adult Participants Aged 1 to 34 Years With Stage 2 Type 1 Diabetes: A Multicenter, Randomized, Open-label, Controlled Study.

Last checked: Nov 20, 2026Latest source record: Nov 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

5

Actual

Start

Jul 25, 2025

Primary completion

Mar 6, 2028

Study completion Mar 6, 2028

Sponsor

Lead sponsor
SanofiSanofi (SNY)
Sponsor type
Industry
First posted
Jan 24, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 1 year, up to 34 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a parallel, Phase 2, two-arm study to assess the efficacy and safety of 14-days intravenous (IV) infusion of teplizumab treatment. Teplizumab has been approved by FDA to delay the onset of Stage 3 Type 1 Diabetes (T1D) in adults and pediatric patients aged 8 years and older with Stage 2 T1D. The dose regimen of teplizumab in this study is consistent with the regimen approved by US FDA. Given prior clinical studies conducted in Western countries, this design is appropriate to assess the efficacy, safety and tolerability, pharmacokinetic, pharmacodynamic, and immunogenicity of a 14-day IV infusion regimen of teplizumab in Japanese Stage 2 T1D participants aged 1 to 34 years.

Conditions

  • Type 1 Diabetes Mellitus

Interventions

  • TeplizumabDrug

    Pharmaceutical form:Solution for injection-Route of administration:Intravenous infusion

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of participants with Stage 3 Type 1 Diabetes based on American Diabetes Association criteriaTime frame: From baseline up to Week 104
  2. Change from baseline in area under the curve (AUC) of C-peptideTime frame: From baseline up to Week 104
  3. Change from baseline in AUC of endogenous insulinTime frame: From baseline up to Week 104
  4. Number of participants with TEAEs, SAEs, AEs leading to permanent study intervention- or study discontinuation; AEs of special interest; number of participants with clinically significant changes in vital signs, ECG, and/or safety laboratory testTime frame: Throughout the study, approximately 756 days

Locations

15 sites in 1 country. Site status is shown where the registry gives one.

  • Investigational Site Number : 3920017

    Fukuoka, Japan

  • Investigational Site Number : 3920016

    Kyoto, Japan

  • Investigational Site Number : 3920014

    Nagasaki, Japan

  • Investigational Site Number : 3920004

    Osaka, Japan

  • Investigational Site Number : 3920020

    Tokyo, Japan

  • Investigational Site Number : 3920003

    Tokyo, Japan

  • Investigational Site Number : 3920015

    Ichikawa, Chiba, Japan

  • Investigational Site Number : 3920011

    Maebashi, Gunma, Japan

  • Investigational Site Number : 3920006

    Sapporo, Hokkaido, Japan

  • Investigational Site Number : 3920018

    Kobe, Hyōgo, Japan

  • Investigational Site Number : 3920009

    Kanazawa, Ishikawa-ken, Japan

  • Investigational Site Number : 3920007

    Yahaba, Iwate, Japan

  • Investigational Site Number : 3920019

    Yokohama, Kanagawa, Japan

  • Investigational Site Number : 3920001

    Iruma, Saitama, Japan

  • Investigational Site Number : 3920010

    Chūō, Yamanashi, Japan

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.